Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for Acquired Blepharoptosis (Droopy Eyelid) in AdultsGlobeNewsWire • 07/09/20
Osmotica Pharmaceuticals US LLC Submits Amended NDA for Arbaclofen Extended Release Tablets to U.S. Food and Drug AdministrationGlobeNewsWire • 06/30/20
Osmotica Pharmaceuticals (OSMT) in Focus: Stock Moves 6.7% HigherZacks Investment Research • 06/23/20
Osmotica Pharmaceuticals plc to Present at Jefferies Virtual Optical Health SummitGlobeNewsWire • 06/16/20
Osmotica Pharmaceuticals PLC (OSMT) CEO Brian Markison on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/13/20
Osmotica Pharmaceuticals plc Reports First Quarter 2020 Results and Provides Business UpdatesGlobeNewsWire • 05/12/20
OSMOTICA PHARM (OSMT) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 05/07/20
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/19/20
Vertical Pharmaceuticals, LLC, an Osmotica Company, Announces Acceptance of New Drug Application by FDA for RVL-1201 (Oxymetazoline Hydrochloride Ophthalmic Solution, 0.1%) for Acquired Blepharoptosis (Droopy Eyelid)GlobeNewsWire • 11/20/19
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/15/19
Osmotica Pharmaceuticals plc Appoints Industry Executive Michael J. DeBiasi to Board of DirectorsGlobeNewsWire • 09/27/19
Vertical Pharmaceuticals LLC, an Osmotica company, Announces Presentation of Phase III RVL-1201 Clinical Trial Data in Patients with Acquired Blepharoptosis (droopy eyelid)GlobeNewsWire • 09/18/19
Vertical Pharmaceuticals, LLC, an Osmotica Company, Announces Submission of New Drug Application for RVL-1201GlobeNewsWire • 09/17/19